Abstract
Anatoxin-a and epibatidine are natural toxins with a high affinity to nicotinic acetylcholine receptors (nAChR). Nicotinic ligands have the potential to become novel therapeutic agents for various cognitive disorders such as Alzheimer’s and Parkinson’s diseases. The determination of the physicochemical and biological properties of anatoxin-a and epibatidine derivatives is important because these might lead to the development of new cholinergic therapeutic agents. To study these features, the toxins and a set of their derivatives were subjected to a molecular modelling study and QSAR analysis. The structural analyses indicated that the geometric and steric features are important determinants of the compound’s activities. The descriptors selected for the QSAR model also highlighted the roles of the geometric and steric features, together with the importance of electronic features.
Similar content being viewed by others
References
Abreu, R. M. V., Ferreira, C. F. R. I., & Queiroz, M. J. R. P. (2009). QSAR model for predicting radical scavenging activity of di(hetero)arylamines derivatives of benzo[b]thiophenes. European Journal of Medicinal Chemistry, 44, 1952–1958. DOI: 10.1016/j.ejmech.2008.11.011.
Andouze, K., Nielsen, E. Ø., Olsen, G. M., Ahring, P., Jørgensen, T. D., Peters, D., Liljefors, T., & Balle, T. (2006). New ligands with affinity for the α4β2 subytpe of nicotinic acetylcholine receptors. Synthesis, receptor binding and 3DQSAR modeling. Journal of Medicinal Chemistry, 49, 3159–3171. DOI: 10.1021/jm058058h.
Cassels, B. K., Bermudez, I., Dajas, F., Abin-Carriquiry, J. A., & Wonnacott, S. (2005). From ligand design to therapeutic efficacy: The challenge for nicotinic receptor research. Drug Discovery Today, 10, 1657–1665. DOI: 10.1016/s1359-6446(05)03665-2.
Damaj, M. I., Creasy, K. R., Grove, A. D., Rosecrans, J. A., & Martin, B. R. (1994). Pharmacological effects of epibatidine optical enantiomers. Brain Research, 664, 34–40. DOI: 10.1016/0006-8993(94)91950-x.
de Melo, E. B. (2012). A new quantitative structure-property relationship model to predict bioconcentration factors of polychlorinated biphenyls (PCBs) in fishes using E-state index and topological descriptors. Ecotoxicology and Environmental Safety, 75, 213–222. DOI: 10.1016/j.ecoenv.2011.08.026.
de Melo, E. B., & Ferreira, M. M. C. (2012). Four-dimensional structure-activity relationship model to predict HIV-1 integrase strand transfer inhibition using LQTA-QSAR methodology. Journal of Chemical Information and Modeling, 52, 1722–1732. DOI: 10.1021/ci300039a.
Devlin, J. P., Edwards, O. E., Gorham, P. R., Hunter, N. R., Pike, R. K., & Stavric, B. (1977). Anatoxin-a, a toxic alkaloid from Anabaena flos-aquae NRC-44h. Canadian Journal of Chemistry, 55, 1367–1371. DOI: 10.1139/v77-189.
Eriksson, L., Jaworska, J., Worth, A. P., Cronin, M. T. D., McDowell, R. M., & Gramatica, P. (2003). Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environmental Health Perspectives, 111, 1361–1375. DOI: 10.1289/ehp.5758.
Ferreira, M. M. C. (2002). Multivariate QSAR. Journal of the Brazilian Chemical Society, 13, 742–753. DOI: 10.1590/s0103-50532002000600004.
Gaudio, A. C., & Zandonade, E. (2001). Proposição, validação e analise dos modelos que correlacionam estrutura quimica e atividade biologica. Quimica Nova, 24, 658.671. DOI: 10.1590/s0100-40422001000500013. (in Portuguese)
Gohlke, H., Schwarz, S., Gündisch, D., Tilotta, M. C., Weber, A., Wegge, T., & Seitz, G. (2003). 3D QSAR analyses-guided rational design of novel ligands for the (α4)2(β2)3 nicotinic acetylcholine receptor. Journal of Medicinal Chemistry, 46, 2031.2048. DOI: 10.1021/jm020859m.
Golbraikh, A., & Tropsha, A. (2002). Beware of q 2! Journal of Molecular Graphics and Modelling, 20, 269–276. DOI: 10.1016/s1093-3263(01)00123-1.
Hernández, N., Kiralj, R., Ferreira, M. M. C., & Talavera, I. (2009). Critical comparative analysis, validation and interpretation of SVM and PLS regression models in a QSAR study on HIV-1 protease inhibitors. Chemometrics and Intelligent Laboratory Systems, 98, 65–77. DOI: 10.1016/j.chemolab.2009.04.012.
Infometrix (2007). Pirouette 4 [computer software]. Bothell, WA, USA: Infometrix.
Karig, G., Large, J.M., Sharples, C. G. V., Sutherland, A., Gallagher, T., & Wonnacott, S. (2003). Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with α7 selectivity. Bioorganic & Medicinal Chemistry Letters, 13, 2825–2828. DOI: 10.1016/s0960-894x(03)00594-8.
Katritzky, A. R., Petrukhin, R., Tatham, D., Basak, S., Benfenatim, E., Karelson, M., & Maran, U. (2001). Interpretation of quantitative structure-property and -activity relationships. Journal of Chemical Information and Modeling, 41, 679–685. DOI: 10.1021/ci000134w.
Kiralj, R., & Ferreira, M. M. C. (2009). Basic validation procedures for regression models in QSAR and QSPR studies: Theory and application. Journal of Brazilian Chemical Society, 20, 770–787. DOI: 10.1590/s0103-50532009000400021.
Kubinyi, H., Hamprecht, F. A., & Mietzner, T. (1998). Three-dimensional quantitative similarity-activity relationships (3D QSAR) from SEAL similarity matrices. Journal of Medicinal Chemistry, 41, 2553–2564. DOI: 10.1021/jm970732a.
LeSage, M. G., Shelley, D., Ross, J. T., Carroll, F. I., & Corrigall, W. A. (2009). Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacology Biochemistry and Behaviour, 91, 461–467. DOI: 10.1016/j.pbb.2008.08.024.
Liu, P. X:, & Long, W. (2009). Current mathematical methods used in QSAR/QSPR studies. International Journal of Molecular Sciences, 10, 1978–1998. DOI: 10.3390/ijms10051978.
Luan, F., Melo, A., Borges, F., & Cordeiro, M. N. D. S. (2011). Affinity prediction on A3 adenosine receptor antagonists: The chemometric approach. Bioorganic & Medicinal Chemistry, 19, 6853–6859. DOI: 10.1016/j.bmc.2011.09.032.
Martins, J. P. A., & Ferreira, M. M. C. (2013). QSAR modeling: A new open source computational package to generate and validate QSAR models. Quimica Nova, 36, 554–560. DOI: 10.1590/s0100-40422013000400013.
Melagraki, G., Afantitis, A., Sarimveis, H., Koutentis, P. A., Markopoulos, J., & Igglessi-Markopoulou, O. (2007). Optimization of biaryl piperidine and 4-amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques and virtual screening. Journal of Computer-Aided Molecular Design, 21, 251–267. DOI: 10.1007/s10822-007-9112-4.
Molloy, L., Wonnacott, S., Gallagher, T., Brough, P. A., & Livett, B. G. (1995). Anatoxin-a is a potent agonist of the nicotinic acetylcholine receptor of bovine adrenal chromaffin cells. European Journal of Pharmacology: Molecular Pharmacology, 289, 447–453. DOI: 10.1016/0922-4106(95)90153-1.
Molfetta, F. A., Bruni, A. T., Rosseli, F. P., & da Silva, A. B. F. (2007). A partial least squares and principal component regression study of quinone compounds with trypanocidal activity. Structural Chemistry, 18, 49–57. DOI: 10.1007/s11224-006-9120-3.
Nicolotti, O., Pellegrini-Calace, M., Altomare, C., Carotti, A., Carrieri, A., & Sanz, F. (2002). Ligands of neuronal nicotinic acetylcholine receptor (nAChR): Inferences from the Hansch and 3-D quantitative structure-activity relationship (QSAR) models. Current Medicinal Chemisty, 9, 1–29. DOI: 10.2174/0929867023371463.
OECD (2007). Guidance document on the validation of (Q)SAR models. Retrieved November 20, 2012, from http://search. oecd.org/officialdocuments/displaydocumentpdf/?doclanguage=en&cote=env/jm/mono(2007)2
Ojha, P. K., Mitra, I., Das, R. N., & Roy, K. (2011). Further exploring r 2m metrics for validation of QSPR models. Chemometrics and Intelligent Laboratory Systems, 107, 194–205. DOI: 10.1016/j.chemolab.2011.03.011.
Ojha, P. K., & Roy, K. (2011). Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometrics and Intelligent Laboratory Systems, 109, 146–161. DOI: 10.1016/j.chemolab.2011.08.007.
Osswald, J., Rellan, S., Gago, A., & Vasconcelos, V. (2007). Toxicology and detection methods of the alkaloid neurotoxin produced by cyanobacteria, anatoxin-a. Environment International, 33, 1070–1089. DOI: 10.1016/j.envint.2007.06.003.
Papa, E., Dearden, J. C., & Gramatica, P. (2007). Linear QSAR regression models for the prediction of bioconcentration factors by physicochemical properties and structural theoretical molecular descriptors. Chemosphere, 67, 351–358. DOI: 10.1016/j.chemosphere.2006.09.079.
Papke, R. L. (2010). α4β2 Nicotinic acetylcholine receptors, willing if able. British Journal of Pharmacology, 160, 1903–1905. DOI: 10.1111/j.1476-5381.2010.00868.x.
Pérez, X. A., & Quik, M. (2011). Focus on α4β2* and α6β2* nAChRs for Parkinson’s disease therapeutics. Molecular and Cellular Pharmacology, 3, 1–6.
Rapier, C., Lunt, G. G., & Wonnacott, S. (1990). Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: Pharmacological characterisation. Journal of Neurochemistry, 54, 937–945. DOI: 10.1111/j.1471-4159.1990.tb02341.x.
Ribeiro, F. A. L., & Ferreira, M. M. C. (2003). QSPR models of boiling point, octanol.water partition coefficient and retention time index of polycyclic aromatic hydrocarbons. Jour nal of Molecular Structure: Theochem, 663, 109–126. DOI: 10.1016/j.theochem.2003.08.107.
Sharpless, C. G. V., Karig, G., Simpson, G. L., Spencer, J. A., Wright, E., Millar, N. S., Wonnacott, S., & Gallagher, T. (2002). Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (±)-UB-165. Journal of Medicinal Chemistry, 45, 3235–3245. DOI: 10.1021/jm020814l.
Silla, J. M., Nunes, C. A., Cormanich, R. A., Guerreiro, M. C., Ramalho, T. C., & Freitas, M. P. (2011). MIA-QSPR and effect of variable selection on the modeling of kinetic parameters related to activities of modified peptides against dengue type 2. Chemometrics and Intelligent Laboratory Systens, 108, 146–149. DOI: 10.1016/j.chemolab.2011.06.009.
Spande, T. F., Garraffo, H. M., Edwards, M. W., Yeh, H. J. C., Pannell, L., & Daly, J. W. (1992). Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. Journal of the American Chemical Society, 114, 3475–3478. DOI: 10.1021/ja00035a048.
Stanton, M. L. (2003). Interacting guilds: Moving beyond the pairwise perspective on mutualisms. The American Naturalist, 162, S10–S23. DOI: 10.1086/378646.
Talete (2010). Dragon 6.0 [computer software]. Milano, Italy: Talete.
Talete (2011). Dragon 6.0 [computer software], users guide. Milano, Italy: Talete.
Teofilo, R. F., Martins, J. P. A., & Ferreira, M. M C. (2009). Sorting variables by using informative vectors as a strategy for feature selection in multivariate regression. Journal of Chemometrics, 23, 32–48. DOI: 10.1002/cem.1192.
Thomas, P., Stephens, M., Wilkie, G., Amar, M., Lunt, G. G., Whiting, P., Gallagher, T., Pereira, E., Alkodon, M., Albuquerque, E. X., & Wonnacott, S. (1993). (+)-Anatoxin-a is a potent agonist at neuronal nicotinic acetylcholine receptors. Journal of Neurochemistry, 60, 2308–2311. DOI: 10.1111/j.1471-4159.1993.tb03519.x.
Todeschini, R. C., & Consonni, V. (2009). Molecular descriptors for chemoinformatics (2th ed.). Weinheim, Germany: Wiley.
Tonder, J. E., & Olesen, P. H. (2001). Agonists at the α4β2 nicotinic acetylcholine receptors relationships and molecular modeling. Current Medicinal Chemistry, 8, 651.674. DOI: 10.2174/0929867013373165.
Tropsha, A. (2010). Best practices for QSAR model development, validation and exploitation. Molecular Informatics, 29, 476–488. DOI: 10.1002/minf.201000061.
van Drie, J. (2003). Pharmacophore discovery — lessons learned. Current Pharmaceutical Design, 9, 1649–1664. DOI: 10.2174/1381612033454568.
Wold, S., Eriksson, L., & Clementi, S. (1995). Validation tools. In H. van de Waterbeemd (Ed.), Chemometric methods in molecular design (pp. 309–318). Weinheim, Germany: Wiley. DOI: 10.1002/9783527615452.ch5.
Wold, S., Sjöström, M., & Eriksson, L. (2001). PLS-regression: A basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems, 58, 109–130. DOI: 10.1016/s0169-7439(01)00155-1.
Wonnacott, S., Jackman, S., Swanson, K. L., Rapoport, H., & Albuquerque, E. X. (1991). Nicotinic pharmacology of anatoxin analogs. II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. Journal of Pharmacology and Experimental Therapeutics, 259, 387–391.
Wonnacott, S., Swanson, K. L., Albuquerque, E. X., Huby, N. J. S., Thompson, P., & Gallagher, T. (1992). Homoanatoxin: A potent analogue of anatoxin-a. Biochemical Pharmacology, 43, 419–423. DOI: 10.1016/0006-2952(92)90558-z.
Wonnacott, S., & Gallagher, T. (2006). The chemistry and pharmacology of anatoxin-a and related homotropanes with respect to nicotinic acetylcholine receptors. Marine Drugs, 4, 228–254. DOI: 10.3390/md403228.
Wright, E., Gallagher, T., Sharples, C. G. V., & Wonnacott, S. (1997). Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/epibatidine hybrid. Bioorganic & Medicinal Chemistry Letters, 7, 2867–2870. DOI: 10.1016/s0960-894x(97)10090-7.
Zhang, H. B., Liu, C. P., & Li, H. (2004). CoMFA and CoMSIA studies of nAChRs ligands: Epibatidine analogs. QSAR & Combinatorial Science, 23, 80–88. DOI: 10.1002/qsar.200330851.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
de Melo, E.B., Moura e Silva, S. & Paula, F.R. Molecular modelling and quantitative structure-activity relationship studies of anatoxin-a and epibatidine derivatives with affinity to rodent nAChR receptors. Chem. Pap. 68, 1121–1131 (2014). https://doi.org/10.2478/s11696-014-0545-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11696-014-0545-7